HCV Treatment
FDA Approves Once-Daily Coformulation of AbbVie's Viekira Regimen
- Details
- Category: Approved HCV Drugs
- Published on Friday, 29 July 2016 00:00
- Written by HIVandHepatitis.com
The U.S. Food and Drug Administration (FDA) has approved a new once-daily coformulation of AbbVie's paritaprevir-based "3D" regimen for hepatitis C virus (HCV) genotype 1, to be sold as Viekira XR, the company announced this week. AbbVie also said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on a shorter 12-week course of treatment with Viekirax for HCV genotype 4 patients with liver cirrhosis.
Coverage of 21st International AIDS Conference (AIDS 2016)
- Details
- Category: HIV Treatment
- Published on Thursday, 28 July 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 21st International AIDS Conference (AIDS 2016), held July 18-22, in Durban, South Africa.
Conference highlights include PrEP and other biomedical HIV prevention, HIV cure research, experimental antiretroviral therapy, and access to treatment and prevention for key affected populations.
7/28/16
FDA Approves Gilead's Epclusa Combo Pill for All Hepatitis C Genotypes
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 29 June 2016 00:00
- Written by Liz Highleyman
On June 28 the U.S. Food and Drug Administration (FDA) approved Gilead Sciences Epclusa, a new once-daily combination pill containing sofosbuvir and velpatasvir, for the treatment of adults with hepatitis C virus (HCV) genotypes 1 through 6 -- the first approved oral pangenotypic regimen. While it is more effective against more types of HCV, Epclusa will cost less than most earlier interferon-free direct-acting antiviral regimens.
AASLD/IDSA Hepatitis C Guidelines Updated to Include New Therapies
- Details
- Category: HCV Treatment Guidelines
- Published on Thursday, 07 July 2016 00:00
- Written by Liz Highleyman
The American Association for the Study of Liver Diseases, Infectious Diseases Society of America, and International Antiviral Society-USA this week updated their hepatitis C guidelines to add newly approved direct-acting antiviral (DAA) regimens, offering more options for people with HCV genotypes other than 1 or 4. The full guidance is available online at HCVguidelines.org.
Successful Hepatitis C Treatment Reduces Portal Hypertension
- Details
- Category: HCV Treatment
- Published on Thursday, 23 June 2016 00:00
- Written by Liz Highleyman
Direct-acting antiviral therapy that produces a sustained virological response can lead to reduction in portal vein pressure, which causes some of the most serious complications of cirrhosis, according to a report in the May 26 online edition of the Journal of Hepatology. However, the researchers cautioned, reversal of portal hypertension is less likely if liver damage is too advanced, providing an argument for earlier treatment.
More Articles...
- DDW 2016: Modern DAA Regimens Cost Less Per Cure than Older Hepatitis C Treatments
- EASL 2016: Grazoprevir/ Elbasvir Superior to Sofosbuvir Plus Pegylated Interferon
- DDW 2016: ABT-493 + ABT-530 Cures Most Hepatitis C Patients in SURVEYOR Studies
- DDW 2016: Sofosbuvir/ Velpatasvir Produces High Hepatitis C Cure Rates in ASTRAL Trials
Web Design and Development by